Lataa...
Critical appraisal of bevacizumab in the treatment of ovarian cancer
Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. Two randomized Phase III trials evaluated the combination of bevacizumab plus standard cytotoxic chemotherapy...
Tallennettuna:
| Julkaisussa: | Drug Des Devel Ther |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4423500/ https://ncbi.nlm.nih.gov/pubmed/25960638 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S83275 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|